Akero Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AKRO Nasdaq 8731 https://www.akerotx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akero Therapeutics Inc

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis - Jun 27th, 2022 11:00 am
Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma - Jun 16th, 2022 1:22 pm
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million - Jun 16th, 2022 11:00 am
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH - Jun 13th, 2022 12:00 pm
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference - Jun 1st, 2022 8:05 pm
Akero Therapeutics Reports First Quarter 2022 Financial Results - May 6th, 2022 11:00 am
Akero Therapeutics to Present at Upcoming Healthcare Conferences in May - May 2nd, 2022 11:30 am
We're Hopeful That Akero Therapeutics (NASDAQ:AKRO) Will Use Its Cash Wisely - Mar 7th, 2022 9:13 am
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results - Feb 25th, 2022 12:00 pm
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients - Feb 8th, 2022 1:00 pm
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year? - Jan 14th, 2022 2:40 pm
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference - Jan 4th, 2022 9:05 pm
Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference - Nov 26th, 2021 10:28 pm
Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet - Nov 17th, 2021 3:07 pm
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment - Nov 12th, 2021 1:01 pm
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update - Nov 12th, 2021 12:00 pm
Akero Therapeutics to Present at the Jefferies London Healthcare Conference - Nov 9th, 2021 9:15 pm
Akero Therapeutics’ NASH Treatment Gets Fast Track Designation; Shares Rise - Oct 20th, 2021 2:03 pm
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH - Oct 19th, 2021 8:15 pm
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference - Oct 5th, 2021 12:00 pm